Form 4: LBRX CEO Heather Turner's Stock Options Repriced to IPO Price

LB Pharmaceuticals CEO Heather Turner's stock options were repriced to $15 per share, aligning with the company's initial public offering price.

Summary

• Heather D. Turner, CEO and Director of LB Pharmaceuticals Inc. (LBRX), had her employee stock options repriced on September 10, 2025.
• Options for 175,706 shares and 7,857 shares, previously with an exercise price of $41.84, were effectively exchanged for new options with an exercise price of $15 per share.
• An additional 971,828 employee stock options were granted with an exercise price of $15 per share.
• The new exercise price of $15 represents the initial public offering price of LBRX common stock.
• Vesting schedules for the 175,706 and 7,857 share options include 1/4 vesting on November 18, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service.
• The 971,828 share options will vest 1/4 on September 10, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service.
• Following these transactions, Ms. Turner beneficially owns 1,155,391 derivative securities (employee stock options).

Sentiment

Score: 4

Explanation: While the repricing re-incentivizes the CEO, the underlying reason (stock price decline) is negative. The repricing itself can be viewed negatively by shareholders, but it's a necessary step for management retention. The score reflects the mixed implications, leaning slightly negative due to the implied poor stock performance.

Positives

• The repricing of stock options to $15 per share, the IPO price, restores the incentive value for the CEO, Heather D. Turner, by making the options potentially in-the-money or at-the-money.
• The grant of an additional 971,828 options at the $15 IPO price further aligns management's interests with shareholder value creation from the IPO level.
• The repricing and new grants could enhance management retention and motivation, which is crucial for long-term company performance.

Negatives

• The repricing indicates that the company's stock price has likely fallen significantly below the original option exercise price of $41.84, suggesting poor stock performance since the original grant.
• Shareholders who purchased stock above the $15 IPO price may view the repricing as dilutive or unfair, as management's options are reset while their shares remain underwater.
• The repricing effectively lowers the performance hurdle for management to realize value from their options.

Future Outlook

The repricing and new option grants are intended to re-incentivize the Chief Executive Officer, aligning her long-term compensation with the company's performance from its initial public offering price, subject to continuous service and vesting schedules extending over several years.

Management Comments

• The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock.
• Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

Industry Context

Stock option repricing often occurs in the biotechnology or pharmaceutical industry when a company's stock price has significantly declined, rendering previously granted options 'underwater' and ineffective as an incentive. This practice aims to restore management motivation and retention, which is critical for long-term drug development and commercialization efforts, but can be viewed critically by investors.

Comparison to Industry Standards

• Option repricing is a common, albeit controversial, practice across various industries, particularly in sectors with volatile stock performance or after significant market downturns.
• Companies like Zynga (2012) and Groupon (2012) have previously repriced options, often facing shareholder backlash due to the perceived unfairness to existing shareholders whose shares may be underwater.
• The decision to reprice to the IPO price ($15) is a specific strategy to reset the incentive baseline to the company's public market debut valuation, similar to how some companies might reset to a recent low or a specific strategic valuation point.
• The vesting schedules (1/4 initial, then 36 monthly installments) are standard for long-term equity incentives, designed to promote retention over several years.

Stakeholder Impact

• Shareholders: Potential negative sentiment due to perceived dilution or unfairness if their shares are underwater while management's options are reset. May question past stock performance.
• Employees (Management): Increased motivation and retention for the CEO due to restored incentive value of equity compensation.
• Company: Aims to re-align executive incentives with long-term company performance, potentially improving strategic execution and operational focus.

Next Steps

• Continued vesting of the repriced and newly granted options according to the specified schedules (November 18, 2025, September 10, 2026, and subsequent monthly installments).
• Heather D. Turner's continuous service through vesting dates is required for the options to fully vest.

Key Dates

Recommendation

The repricing of CEO options, while a common practice to re-incentivize management after a significant stock price decline, signals past underperformance. While it may improve management retention and motivation, it also raises questions about the company's trajectory and potential shareholder dilution. Investors should hold to observe if the repricing leads to improved operational performance and stock appreciation, rather than making immediate buy or sell decisions based solely on this compensation adjustment.

Keywords

LB Pharmaceuticals, LBRX, Stock Options, Repricing, CEO Compensation, Executive Compensation, Form 4, Beneficial Ownership, Equity Incentive, IPO Price